310 related articles for article (PubMed ID: 31493794)
21. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
22. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
23. Classification of rhabdomyosarcoma and its molecular basis.
Parham DM; Barr FG
Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
[TBL] [Abstract][Full Text] [Related]
24. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
25. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
26. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
27. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
[TBL] [Abstract][Full Text] [Related]
28. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
[TBL] [Abstract][Full Text] [Related]
29. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
30. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
31. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
[TBL] [Abstract][Full Text] [Related]
32. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
33. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
34. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract][Full Text] [Related]
35. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
[TBL] [Abstract][Full Text] [Related]
36. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
37. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
38. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract][Full Text] [Related]
39. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
[TBL] [Abstract][Full Text] [Related]
40. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.
Rudzinski ER; Anderson JR; Lyden ER; Bridge JA; Barr FG; Gastier-Foster JM; Bachmeyer K; Skapek SX; Hawkins DS; Teot LA; Parham DM
Am J Surg Pathol; 2014 May; 38(5):654-9. PubMed ID: 24618610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
